Sensititre MycoTB plate compared to bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: A call to operationalize MICs

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 7104-7108

  Heysell, Scott K ^a   Pholwat, Suporn ^a   Mpagama, Stellah G ^b   Pazia, Saumu J ^c   Kumburu, Happy ^c   Ndusilo, Norah ^c   Gratz, Jean ^a   Houpt, Eric R ^a   Kibiki, Gibson S ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Kibong'oto Infectious Diseases Hospital   (Tanzania)

^c KILIMANJARO CLINICAL RESEARCH INSTITUTE   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEC MGIT 960; BACTERIUM ISOLATE; CASE REPORT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LABORATORY DEVICE; LIQUID CULTURE; MALE; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITITRE MYCOTB PLATE; SENSITIVITY AND SPECIFICITY; TANZANIA; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TANZANIA;

EID: 84946224104     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01117-15     Document Type: Article

References (15)

1. Ahuja SD, Ashkin D, Avendano M., Banerjee R, Bauer M, Bayona J.N., Becerra MC, Benedetti A, Burgos M, Centis R., Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Pena J, Perez-Guzman C, Quelapio MI, Ponce-de-Leon A. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 9:e1001300. http://dx.doi.org/10.1371/journal.pmed.1001300.
2. Cegielski JP, Dalton T, Yagui M., Wattanaamornkiet W, Volchenkov GV, Via L.E., Van Der Walt M, Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T, Kurbatova E, Kummik T, Kuksa L, Kliiman K, Kiryanova EV, Kim H, Kim CK, Kazennyy BY, Jou R, Huang WL, Ershova J, Erokhin VV, Diem L, Contreras C, Cho SN, Chernousova LN, Chen MP, Caoili JC, Bayona J, Akksilp S. 2014. Extensive drug resistance acquired during treatment of multidrugresistant tuberculosis. Clin Infect Dis 59:1049-1063. http://dx.doi.org/10.1093/cid/ciu572.
3. Heysell SK, Houpt ER 2012. The future of molecular diagnostics for drug-resistant tuberculosis. Expert Rev Mol Diagn 12:395-405. http://dx.doi.org/10.1586/erm.12.25.
4. Kam KM, Sloutsky A, Yip C.W., Bulled N., Seung KJ, Zignol M, Espinal M, Kim SJ 2010. Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 14:282-288.
5. Abuali MM, Katariwala R, LaBombardi VJ 2012. A comparison of the Sensititre MycoTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 31:835-839. http://dx.doi.org/10.1007/s10096-011-1382-z.
6. Hall L, Jude KP, Clark S.L., Dionne K., Merson R, Boyer A, Parrish N.M., Wengenack NL. 2012. Evaluation of the Sensititre MycoTB plate for the susceptibility testing of Mycobacterium tuberculosis complex against first and second line agents. J Clin Microbiol 50:3732-3734. http://dx.doi.org/10.1128/JCM.02048-12.
7. Lee J, Armstrong DT, Ssengooba W, Park J., Yu Y, Mumbowa F, Namaganda C., Mboowa G, Nakayita G, Amakovitch S., Chien G, Cho S-N, Via LE, Barry C.E., Ellner JJ, Alland D, Dorman SE, Joloba ML. 2014. Sensititre MycoTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother 58:11-18. http://dx.doi.org/10.1128/AAC.01209-13.
8. Rüsch-Gerdes S., Pfyffer GE, Casal M, Chadwick M., Siddiqi S. 2006. Multicenter laboratory validation of the Bactec MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical secondline drugs and newer antimicrobials. J Clin Microbiol 44:688-692. http://dx.doi.org/10.1128/JCM.44.3.688-692.2006.
9. Krüüner A, Yates MD, Drobniewski FA. 2006. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 44:811-818. http://dx.doi.org/10.1128/JCM.44.3.811-818.2006.
10. Banu S, Rahman SMM, Khan MSR, Ferdous S, Ahmed S., Gratz J, Stroup S, Pholwat S., Heysell SK, Houpt ER. 2014. Discordance across several drug susceptibility methods for drug-resistant tuberculosis in a single laboratory. J Clin Microbiol 52:156-163. http://dx.doi.org/10.1128/JCM.02378-13.
11. Mpagama S, Ndusilo N, Stroup S., Gratz J, Kumburu H, Moore J.L., Peloquin CA, Houpt ER, Kibiki GS, Heysell SK 2014. Plasma drug activity in patients treated for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 58:782-788. http://dx.doi.org/10.1128/AAC.01549-13.
12. Ndusilo ND, Heysell SK, Mpagama S.G., Gratz J., Segesela FH, Pazia SJ, Houpt ER, Kibiki GS 2015. Improvement in plasma drug activity during the early treatment interval in multidrug-resistant tuberculosis in Tanzania. PLoS One 10:e0122769. http://dx.doi.org/10.1371/journal.pone.0122769.
13. Heysell SK, Moore JR, Peloquin C.A., Ashkin D., Houpt ER. 2015. Outcomes and therapeutic drug monitoring in multidrug-resistant TB patients treated in Virginia, 2009-2014. Tuberc Respir Dis (Seoul) 78:78-84. http://dx.doi.org/10.4046/trd.2015.78.2.78.
14. Heysell SK, Ahmed S, Mazidur SMM, Mahmud AM, Houpt E.R., Banu S. 2015. Quantitative second-line drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice. PLoS One 10:e0116795. http://dx.doi.org/10.1371/journal.pone.0116795.
15. Sotgiu G, Alffenaar JWC, Centis R, D'Ambrosio L, Spanevello A, Piana A., Migliori GB. 2015. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. Int J Infect Dis 32:101-104. http://dx.doi.org/10.1016/j.ijid.2014.12.001.